Goen Technologies, subsidiary company TrimSpa Inc. and its recently deceased spokesperson, Anna Nicole Smith, were named in a class-action lawsuit alleging false and misleading marketing for the TrimSpa X32 weight-loss supplement. The suit was filed Feb. 5 in the California Superior Court of Los Angeles County. Plaintiffs are asking for unspecified damages, restitution and an injunction preventing TrimSpa from making future weight-loss claims. The class action suit quickly follows Goen Technologies' and related marketers' $1.5 mil. settlement with FTC over allegations of unsubstantiated weight-loss claims (1"The Tan Sheet" Jan. 8, 2007, p. 4). TrimSpa's recent legal trouble in conjunction with Smith's death does not bode well for the future of the brand, according to brand consultant Robert K. Passikoff, Ph.D. Not only does the combination of circumstances deliver "too big a hit" for TrimSpa to recover, but there may also be reverberations across the entire weight-loss supplement category, Passikoff said....
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.
